Quantitative PET Imaging with Novel HER3-Targeted Peptides Selected by Phage Display to Predict Androgen-Independent Prostate Cancer Progression
[Technical Report, Final Report]
Massachusetts General Hospital
Pagination or Media Count:
Funding from this award has permitted the development of a highly specific peptide that targets HER3 for prostate cancer imaging. The peptide was labeled with a PET imaging radionuclide and injected into mice bearing human prostate cancer. The peptide accumulated at high levels in the tumors, and excisional analysis revealed quantitative accumulation of the peptide in tumors that was linearly correlated with HER3 levels. Biodistribution analysis revealed low off-target accumulation and rapid clearance through the renal system, consistent with small peptides. The peptide represents a promising clinical lead for HER3 imaging in patients with castration resistant prostate cancer.
- Medicine and Medical Research